MANKIND PHARMA
Back to Income Statement
|
MANKIND PHARMA Last 5 Year Consolidated Net Profit History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Consolidated Net Profit | ₹1,282 Cr | ₹1,433 Cr | ₹127 Cr | ₹10,304 Cr | ₹579 Cr |
What is the latest Consolidated Net Profit of MANKIND PHARMA ?
Year | Consolidated Net Profit |
---|---|
Mar2024 | ₹1,282 Cr |
Mar2023 | ₹1,433 Cr |
Mar2022 | ₹127 Cr |
Mar2021 | ₹10,304 Cr |
Mar2020 | ₹579 Cr |
How is Consolidated Net Profit of MANKIND PHARMA Trending?
Years | Consolidated Net Profit | % Change | |
---|---|---|---|
Mar2024 | ₹1,282 Cr | -10.58 | |
Mar2023 | ₹1,433 Cr | 1,032.80 | |
Mar2022 | ₹127 Cr | -98.77 | |
Mar2021 | ₹10,304 Cr | 1,681.10 | |
Mar2020 | ₹579 Cr | - |
Compare Consolidated Net Profit of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹101,363.4 Cr | 2.4% | 7.1% | 3.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹407,155.0 Cr | -3.9% | 3% | 7.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹147,295.0 Cr | -5% | -1.1% | 71.6% | Stock Analytics | |
CIPLA | ₹116,664.0 Cr | -4.4% | 0.2% | -1.7% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹107,678.0 Cr | -1.6% | 6.5% | 26.2% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹96,162.6 Cr | -2.4% | 2.4% | -5.4% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | 2.4% |
7.1% |
3.9% |
SENSEX | -2.5% |
1.9% |
4.9% |
You may also like the below Video Courses